Search

Your search keyword '"Chen, H.-J."' showing total 34 results

Search Constraints

Start Over You searched for: Author "Chen, H.-J." Remove constraint Author: "Chen, H.-J." Publisher elsevier bv Remove constraint Publisher: elsevier bv
34 results on '"Chen, H.-J."'

Search Results

1. WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

3. P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

4. P1.23-09 Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study

5. P1.09-02 Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC

6. 20P Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)

8. 388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study

9. 1266P Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets

10. 1741P Malignant effusion-derived non-small cell lung cancer organoid might be a feasible in vitro model for therapeutic screening

11. Histone methyltransferase DOT1L regulates macrophage inflammatory responses and lipid metabolism

12. The polycomb repressive complex 2 (PRC2) in macrophages and atherosclerosis

13. 32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC)

14. Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505)

16. CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study

26. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

33. 2429

Catalog

Books, media, physical & digital resources